Compare · MASS vs TMO
MASS vs TMO
Side-by-side comparison of 908 Devices Inc. (MASS) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MASS and TMO operate in Industrial Machinery/Components (Industrials), so they compete in similar markets.
- TMO is the larger of the two at $174.42B, about 528.4x MASS ($330.1M).
- Over the past year, MASS is up 32.5% and TMO is up 16.2% - MASS leads by 16.4 points.
- MASS has been more active in the news (12 items in the past 4 weeks vs 4 for TMO).
- TMO has more recent analyst coverage (25 ratings vs 5 for MASS).
- Company
- 908 Devices Inc.
- Thermo Fisher Scientific Inc
- Price
- $8.74+0.92%
- $469.55+1.19%
- Market cap
- $330.1M
- $174.42B
- 1M return
- +23.10%
- +4.51%
- 1Y return
- +32.52%
- +16.17%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 12
- 4
- Recent ratings
- 5
- 25
908 Devices Inc.
908 Devices Inc. develops and sells measurement devices for chemical and biochemical analysis in North America, Europe, the Middle East, Africa, and the Asia Pacific. It offers handheld and desktop mass spectrometry (Mass Spec) devices for the point-of-need applications in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets. Its products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of gas, liquid, and solid materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and ZipChip, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. 908 Devices Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest MASS
- SEC Form 4 filed by Director Vann Brandi C
- Director Leonhart Michele M. converted options into 14,083 shares, increasing direct ownership by 217% to 20,568 units (SEC Form 4)
- Director Hrusovsky E Kevin converted options into 14,083 shares, increasing direct ownership by 9% to 165,390 units (SEC Form 4)
- Director Hunt Anthony converted options into 14,083 shares, increasing direct ownership by 47% to 44,168 units (SEC Form 4)
- Director Eloi Fenel M converted options into 14,083 shares, increasing direct ownership by 53% to 40,897 units (SEC Form 4)
- Director Crandell Keith converted options into 14,083 shares, increasing direct ownership by 56% to 39,374 units (SEC Form 4)
- Director Spoto Mark converted options into 14,083 shares, increasing direct ownership by 19% to 89,346 units (SEC Form 4)
- 908 Devices Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Brown Christopher D. sold $900 worth of shares (100 units at $9.00) as part of a pre-agreed trading plan, decreasing direct ownership by 0.01% to 875,459 units (SEC Form 4)
- Large owner Awm Investment Company, Inc. sold $379,231 worth of 908 DEVICES (42,282 units at $8.97) (SEC Form 4)
Latest TMO
- SEC Form 11-K filed by Thermo Fisher Scientific Inc
- Piper Sandler initiated coverage on Thermo Fisher with a new price target
- Thermo Fisher downgraded by HSBC Securities with a new price target
- Wolfe Research resumed coverage on Thermo Fisher with a new price target
- SEC Form SD filed by Thermo Fisher Scientific Inc
- Thermo Fisher Scientific Unveils Next-generation Innovations at ASMS 2026 to Accelerate the Path from Drug Discovery to New Therapies
- Thermo Fisher Scientific Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Weisler Dion J covered exercise/tax liability with 80 shares and was granted 499 shares, increasing direct ownership by 8% to 5,446 units (SEC Form 4)
- Director Sperling Scott M was granted 499 shares, increasing direct ownership by 0.72% to 69,479 units (SEC Form 4)
- Director Spar Debora L was granted 499 shares, increasing direct ownership by 24% to 2,610 units (SEC Form 4)